kabutan

HEALIOS K.K.(4593) Summary

4593
TSE Growth
HEALIOS K.K.
322
JPY
-20
(-5.85%)
Apr 28, 3:30 pm JST
2.02
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
322
Apr 28, 11:56 pm JST
Summary Chart Historical News Financial Result
PER
PBR
8.89
Yield
ー%
Margin Trading Ratio
18.69
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
341 JPY 2.13 USD
Previous Close Apr 27
342 JPY 2.14 USD
High Apr 28, 9:01 am
344 JPY 2.15 USD
Low Apr 28, 1:46 pm
309 JPY 1.94 USD
Volume
4,912,900
Trading Value
1.59B JPY 0.01B USD
VWAP
324.14 JPY 2.04 USD
Minimum Trading Value
32,200 JPY 202 USD
Market Cap
0.04T JPY 0.27B USD
Number of Trades
1,803
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
2,816
1-Year High Jul 17, 2025
31,879
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 790,700 11,338,800 14.34
Apr 17, 2026 1,838,400 10,953,200 5.96
Apr 10, 2026 1,836,500 10,814,000 5.89
Apr 3, 2026 1,811,700 11,294,200 6.23
Mar 27, 2026 1,839,700 11,323,200 6.15
Company Profile
HEALIOS K.K. develops treatments for intractable diseases using iPS cells. The company collaborates with Sumitomo Pharma and has a business alliance with Nikon.
Sector
Pharmaceuticals
HEALIOS K.K. conducts research and development of regenerative medicine products utilizing iPS cell technology. In the field of somatic stem cell regenerative medicine, the company is advancing the development of HLCM051 for acute cerebral infarction and ARDS (Acute Respiratory Distress Syndrome). In the iPSC regenerative medicine field, which involves transplanting cells with functions similar to the human body created by differentiating iPS cells, HEALIOS K.K. is developing a next-generation platform to create Universal Donor Cells (UDC) with reduced risk of immune rejection. The company's pipeline includes research and development in cancer immunotherapy, age-related macular degeneration treatment, and liver disease treatment. Through joint development with Sumitomo Pharma and collaborations with domestic and international research institutions, HEALIOS K.K. aims to realize new treatments for intractable diseases.